AMR Bacterial Infections — Deal Benchmarks & Valuation
Market Analysis
AMR Bacterial Infections is one of the most actively transacted indications in infectious disease licensing. Phase 2 deals for amr bacterial infections carry a median total deal value of $3.2B, with upfront payments ranging from $487M to $1.2B. The recommended deal structure allocates approximately 26% to upfront payments and 74% to milestones.
Milestone structures for amr bacterial infections deals allocate $520M to development milestones, $544M to regulatory milestones, and $1.3B to commercial milestones. Royalty rates range from 9% to 17.9% at the base tier, with tiered escalation reaching 13%-21.9% on peak sales.
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
What are typical deal terms for amr bacterial infections licensing?
What royalty rates are standard for amr bacterial infections deals?
How are amr bacterial infections deal milestones structured?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.
Start CalculatingNeed the full deal landscape?
The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.